XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
RESTRUCTURING
 9 Months Ended
Jan. 01, 2022
Restructuring and Related Activities [Abstract]  
RESTRUCTURING
3. RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.
In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During the first quarter of fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company now expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During the three and nine months ended January 1, 2022, the Company incurred $5.7 million and $20.2 million, respectively, of restructuring and restructuring related costs under this program. During the three and nine months ended December 26, 2020, the Company incurred $3.1 million and $11.1 million, respectively, of restructuring and restructuring related costs under this program. Total cumulative charges under this program are $47.2 million.

The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the nine months ended January 1, 2022, substantially all of which relates to employee severance and other employee costs:
(In thousands)2020 ProgramPrior ProgramsTotal
Balance at April 3, 2021$575 $437 $1,012 
Costs incurred, net of reversals4,008 28 4,036 
Payments(1,988)(33)(2,021)
Balance at January 1, 2022$2,595 $432 $3,027 

The following presents the restructuring costs by line item within our accompanying unaudited Condensed Consolidated Statements of Income and Comprehensive Income:
 Three Months EndedNine Months Ended
(In thousands) January 1,
2022		December 26,
2020		January 1,
2022		December 26,
2020
Cost of goods sold$(187)$(49)$2,276 $218 
Research and development— (2)108 108 
Selling, general and administrative expenses108 (41)1,652 574 
$(79)$(92)$4,036 $900 

As of January 1, 2022, the Company had a restructuring liability of $3.0 million, of which $2.6 million is payable within the next twelve months.

In addition to the restructuring costs included in the table above, the Company also incurred costs that do not constitute restructuring under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards.
The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costsThree Months EndedNine Months Ended
(In thousands) January 1, 2022December 26, 2020January 1, 2022December 26, 2020
Plasma$(192)$(27)$2,507 $454 
Blood Center— 66 3 240 
Hospital— — (91)(18)
Corporate113 (131)1,617 224 
Total$(79)$(92)$4,036 $900 
Restructuring related costsThree Months EndedNine Months Ended
(In thousands) January 1, 2022December 26, 2020January 1, 2022December 26, 2020
Plasma$1,400 $431 $4,541 $1,235 
Blood Center24 518 554 1,024 
Hospital127 4 292 14 
Corporate4,210 2,282 10,827 8,410 
Total$5,761 $3,235 $16,214 $10,683 
Total restructuring and restructuring related costs$5,682 $3,143 $20,250 $11,583